232 related articles for article (PubMed ID: 37002471)
1. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
[TBL] [Abstract][Full Text] [Related]
2. Evaluating Oral Probiotic Supplements as Complementary Treatment in Advanced Lung Cancer Patients Receiving ICIs: A Prospective Real-World Study.
Tong L; Wan Y; Shi X; Liu X; Liu Z; Li Y; Zhang Y; Luo D; Zhu J
Cancer Control; 2024; 31():10732748241253959. PubMed ID: 38736182
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of extracranial stereotactic body radiation therapy for induced oligometastatic non-small cell lung cancer on novel systemic therapy.
Tsur E; Blumenfeld P; Rottenberg Y; Nechushtan H; Arnon J; Wald O; Izhar U; Pfeffer R; Krakow A; Wygoda M; Popovtzer A; Michaeli TF
Transl Lung Cancer Res; 2024 Mar; 13(3):465-474. PubMed ID: 38601442
[TBL] [Abstract][Full Text] [Related]
4. Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E
Christ SM; Alongi F; Ricardi U; Scorsetti M; Livi L; Balermpas P; Lievens Y; Braam P; Jereczek-Fossa BA; Stellamans K; Ratosa I; Widder J; Peulen H; Dirix P; Bral S; Ramella S; Hemmatazad H; Khanfir K; Geets X; Jeene P; Zilli T; Fournier B; Ivaldi GB; Clementel E; Fortpied C; Oppong FB; Ost P; Guckenberger M
Radiother Oncol; 2024 Jun; 195():110235. PubMed ID: 38508239
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density as an individual prognostic biomarker in NSCLC patients treated with immune checkpoint inhibitors.
Lou J; Gong B; Li Y; Guo Y; Li L; Wang J; Liu W; You Z; Zhang H; Pan F; Liang B; Yang L; Zhou G
Front Immunol; 2024; 15():1332303. PubMed ID: 38698843
[TBL] [Abstract][Full Text] [Related]
6. Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial.
Bassetti MF; Morris BA; Sethakorn N; Lang JM; Schehr JL; Zhao SG; Morris ZS; Buehler D; Eickhoff JC; Harari PM; Traynor AM; Campbell TC; Baschnagel AM; Leal TA
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1481-1489. PubMed ID: 38072321
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer.
Zhu J; Yu Y; Mei J; Chen S; Li J; Jiang S
Front Immunol; 2023; 14():1278573. PubMed ID: 38124737
[TBL] [Abstract][Full Text] [Related]
8. Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials.
Lynch C; Korpics MC; Katipally RR; Wu T; Bestvina CM; Pitroda S; Chmura SJ; Juloori A
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1519-1530. PubMed ID: 38199382
[TBL] [Abstract][Full Text] [Related]
9. Effect of body mass index and cholesterol-rich apolipoprotein-B-containing lipoproteins on clinical outcome in NSCLC patients treated with immune checkpoint inhibitors-based therapy: A retrospective analysis.
Hu Z; Zheng Y; Zheng J; Wang Y; Liao J; Liu Z; Li J; Cui H
Cancer Med; 2024 Jun; 13(11):e7241. PubMed ID: 38819098
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of stereotactic radiotherapy on elderly patients with stage I-II central non-small cell lung cancer.
Ji X; Zhou B; Huang H; Wang Y; Jiang W; Wang J; Ding W; Wang Z; Chen G; Sun X
Front Oncol; 2024; 14():1235630. PubMed ID: 38803531
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study.
Shepard MJ; Xu Z; Donahue J; Eluvathingal Muttikkal TJ; Cordeiro D; Hansen L; Mohammed N; Gentzler RD; Larner J; Fadul CE; Sheehan JP
J Neurosurg; 2019 Jul; 133(3):685-692. PubMed ID: 31349225
[TBL] [Abstract][Full Text] [Related]
12. Utility of molecular markers in predicting local control specific to lung cancer spine metastases treated with stereotactic body radiotherapy.
Shor D; Louie AV; Zeng KL; Menjak IB; Atenafu EG; Chia-Lin Tseng ; Detsky J; Larouche J; Zhang B; Soliman H; Myrehaug S; Maralani P; Hwang DM; Sahgal A; Chen H
J Neurooncol; 2024 Apr; 167(2):275-283. PubMed ID: 38526757
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence.
Huang L; Chen S; Liu H; Meng L; Liu C; Wu X; Wang Y; Luo S; Tu H; Wang C; Zhang M; Gong X
Cancer Med; 2024 Apr; 13(7):e7125. PubMed ID: 38613182
[TBL] [Abstract][Full Text] [Related]
14. A real-world analysis of stereotactic body radiotherapy combined with immunotherapy in advanced or recurrent non-small cell lung cancer (NSCLC): A single-center experience.
Yao D; Zhu X; Guo J; Dong X; Zeng Y; Fu X; Yu W
Clin Transl Radiat Oncol; 2024 Jul; 47():100787. PubMed ID: 38770061
[TBL] [Abstract][Full Text] [Related]
15. Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients.
Xu Y; Zhang Q; Chen Z; Yang S; Chen H; Xiao X; Jiang H
BMC Pulm Med; 2024 Apr; 24(1):174. PubMed ID: 38609918
[TBL] [Abstract][Full Text] [Related]
16. Impact of Cardiac Dose on Overall Survival in Lung Stereotactic Body Radiotherapy (SBRT) Compared to Conventionally Fractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC).
Anderson JD; Hu J; Li J; Schild SE; Fatyga M
J Cancer Ther; 2021 Jul; 12(7):409-423. PubMed ID: 34367717
[TBL] [Abstract][Full Text] [Related]
17. The impact of pulmonary artery to ascending aorta diameter ratio progression on the prognosis of NSCLC patients treated with immune checkpoint inhibitors.
Gong B; Li Y; Guo Y; Wang J; Liu W; Zhou G; Song J; Pan F; Yang L; Liang B
Front Immunol; 2024; 15():1302233. PubMed ID: 38348049
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone.
Dohm AE; Tang JD; Mills MN; Liveringhouse CL; Sandoval ML; Perez BA; Robinson TJ; Creelan BC; Gray JE; Etame AB; Vogelbaum MA; Forsyth P; Yu HM; Oliver DE; Ahmed KA
J Neurosurg; 2023 Jun; 138(6):1600-1607. PubMed ID: 36681988
[TBL] [Abstract][Full Text] [Related]
19. Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer.
Cheruvu P; Metcalfe SK; Metcalfe J; Chen Y; Okunieff P; Milano MT
Radiat Oncol; 2011 Jun; 6():80. PubMed ID: 21718501
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of definitive chemoradiotherapy with or without induction immune checkpoint inhibitors in patients with stage III non-small cell lung cancer.
Yang Y; Wang J; Zhang T; Zhou Z; Wang Y; Jiang Y; Liu W; Xiao Z; Deng L; Feng Q; Wang X; Lv J; Wang W; Xue Q; Wang J; Li YX; Bi N
Front Immunol; 2023; 14():1281888. PubMed ID: 38077319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
